vs

Side-by-side financial comparison of Silvercrest Asset Management Group Inc. (SAMG) and Xtant Medical Holdings, Inc. (XTNT). Click either name above to swap in a different company.

Xtant Medical Holdings, Inc. is the larger business by last-quarter revenue ($32.4M vs $32.0M, roughly 1.0× Silvercrest Asset Management Group Inc.). Xtant Medical Holdings, Inc. runs the higher net margin — 0.2% vs -0.4%, a 0.6% gap on every dollar of revenue. On growth, Xtant Medical Holdings, Inc. posted the faster year-over-year revenue change (2.7% vs -0.0%). Silvercrest Asset Management Group Inc. produced more free cash flow last quarter ($15.0M vs $5.0M). Over the past eight quarters, Xtant Medical Holdings, Inc.'s revenue compounded faster (7.7% CAGR vs 2.7%).

Xtant Medical Holdings, Inc. is a global medical technology company that develops, manufactures and markets orthobiologic products, neurosurgery devices, and regenerative medicine solutions for orthopedic and neurological care providers. It serves patients and medical institutions across North America, Europe and the Asia-Pacific, with core segments covering spinal surgery supplies and bone regeneration products.

SAMG vs XTNT — Head-to-Head

Bigger by revenue
XTNT
XTNT
1.0× larger
XTNT
$32.4M
$32.0M
SAMG
Growing faster (revenue YoY)
XTNT
XTNT
+2.7% gap
XTNT
2.7%
-0.0%
SAMG
Higher net margin
XTNT
XTNT
0.6% more per $
XTNT
0.2%
-0.4%
SAMG
More free cash flow
SAMG
SAMG
$10.0M more FCF
SAMG
$15.0M
$5.0M
XTNT
Faster 2-yr revenue CAGR
XTNT
XTNT
Annualised
XTNT
7.7%
2.7%
SAMG

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
SAMG
SAMG
XTNT
XTNT
Revenue
$32.0M
$32.4M
Net Profit
$-120.0K
$57.0K
Gross Margin
54.9%
Operating Margin
-2.8%
-2.9%
Net Margin
-0.4%
0.2%
Revenue YoY
-0.0%
2.7%
Net Profit YoY
-107.4%
101.8%
EPS (diluted)
$0.02
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SAMG
SAMG
XTNT
XTNT
Q4 25
$32.0M
$32.4M
Q3 25
$31.3M
$33.3M
Q2 25
$30.7M
$35.4M
Q1 25
$31.4M
$32.9M
Q4 24
$32.0M
$31.5M
Q3 24
$30.4M
$27.9M
Q2 24
$31.0M
$29.9M
Q1 24
$30.3M
$27.9M
Net Profit
SAMG
SAMG
XTNT
XTNT
Q4 25
$-120.0K
$57.0K
Q3 25
$618.0K
$1.3M
Q2 25
$1.9M
$3.5M
Q1 25
$2.5M
$58.0K
Q4 24
$1.6M
$-3.2M
Q3 24
$2.3M
$-5.0M
Q2 24
$2.7M
$-3.9M
Q1 24
$3.0M
$-4.4M
Gross Margin
SAMG
SAMG
XTNT
XTNT
Q4 25
54.9%
Q3 25
66.1%
Q2 25
68.6%
Q1 25
61.5%
Q4 24
50.9%
Q3 24
58.4%
Q2 24
62.1%
Q1 24
62.1%
Operating Margin
SAMG
SAMG
XTNT
XTNT
Q4 25
-2.8%
-2.9%
Q3 25
4.3%
7.6%
Q2 25
13.2%
13.1%
Q1 25
15.4%
3.2%
Q4 24
6.1%
-6.0%
Q3 24
14.6%
-13.5%
Q2 24
17.1%
-9.8%
Q1 24
19.5%
-12.4%
Net Margin
SAMG
SAMG
XTNT
XTNT
Q4 25
-0.4%
0.2%
Q3 25
2.0%
3.9%
Q2 25
6.3%
10.0%
Q1 25
7.9%
0.2%
Q4 24
5.1%
-10.0%
Q3 24
7.4%
-18.0%
Q2 24
8.6%
-12.9%
Q1 24
9.9%
-15.8%
EPS (diluted)
SAMG
SAMG
XTNT
XTNT
Q4 25
$0.02
$0.00
Q3 25
$0.07
$0.01
Q2 25
$0.21
$0.02
Q1 25
$0.26
$0.00
Q4 24
$0.16
$-0.02
Q3 24
$0.24
$-0.04
Q2 24
$0.28
$-0.03
Q1 24
$0.32
$-0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SAMG
SAMG
XTNT
XTNT
Cash + ST InvestmentsLiquidity on hand
$44.1M
$17.1M
Total DebtLower is stronger
$11.0M
Stockholders' EquityBook value
$50.3M
$51.0M
Total Assets
$166.6M
$94.1M
Debt / EquityLower = less leverage
0.22×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SAMG
SAMG
XTNT
XTNT
Q4 25
$44.1M
$17.1M
Q3 25
$36.1M
$10.4M
Q2 25
$30.0M
$6.9M
Q1 25
$36.3M
$5.0M
Q4 24
$68.6M
$6.2M
Q3 24
$58.1M
$6.6M
Q2 24
$49.9M
$5.4M
Q1 24
$39.7M
$4.5M
Total Debt
SAMG
SAMG
XTNT
XTNT
Q4 25
$11.0M
Q3 25
$17.4M
Q2 25
$22.3M
Q1 25
$22.2M
Q4 24
$22.0M
Q3 24
$19.1M
Q2 24
$21.8M
Q1 24
$16.8M
Stockholders' Equity
SAMG
SAMG
XTNT
XTNT
Q4 25
$50.3M
$51.0M
Q3 25
$58.9M
$50.4M
Q2 25
$64.6M
$48.5M
Q1 25
$80.0M
$43.9M
Q4 24
$80.7M
$43.0M
Q3 24
$84.6M
$45.7M
Q2 24
$85.3M
$45.0M
Q1 24
$83.9M
$47.7M
Total Assets
SAMG
SAMG
XTNT
XTNT
Q4 25
$166.6M
$94.1M
Q3 25
$157.6M
$106.3M
Q2 25
$152.7M
$103.5M
Q1 25
$159.9M
$95.8M
Q4 24
$194.4M
$93.8M
Q3 24
$184.2M
$98.9M
Q2 24
$177.6M
$95.6M
Q1 24
$170.2M
$93.9M
Debt / Equity
SAMG
SAMG
XTNT
XTNT
Q4 25
0.22×
Q3 25
0.35×
Q2 25
0.46×
Q1 25
0.51×
Q4 24
0.51×
Q3 24
0.42×
Q2 24
0.48×
Q1 24
0.35×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SAMG
SAMG
XTNT
XTNT
Operating Cash FlowLast quarter
$18.6M
$5.4M
Free Cash FlowOCF − Capex
$15.0M
$5.0M
FCF MarginFCF / Revenue
46.9%
15.4%
Capex IntensityCapex / Revenue
11.4%
1.2%
Cash ConversionOCF / Net Profit
94.39×
TTM Free Cash FlowTrailing 4 quarters
$17.0M
$10.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SAMG
SAMG
XTNT
XTNT
Q4 25
$18.6M
$5.4M
Q3 25
$14.6M
$4.6M
Q2 25
$13.8M
$1.3M
Q1 25
$-24.7M
$1.3M
Q4 24
$21.6M
$665.0K
Q3 24
$13.3M
$-1.7M
Q2 24
$16.0M
$-5.1M
Q1 24
$-24.1M
$-5.8M
Free Cash Flow
SAMG
SAMG
XTNT
XTNT
Q4 25
$15.0M
$5.0M
Q3 25
$13.8M
$4.2M
Q2 25
$13.4M
$910.0K
Q1 25
$-25.1M
$87.0K
Q4 24
$19.9M
$-7.0K
Q3 24
$12.9M
$-3.8M
Q2 24
$15.6M
$-5.7M
Q1 24
$-24.7M
$-6.5M
FCF Margin
SAMG
SAMG
XTNT
XTNT
Q4 25
46.9%
15.4%
Q3 25
44.1%
12.6%
Q2 25
43.6%
2.6%
Q1 25
-80.0%
0.3%
Q4 24
62.2%
-0.0%
Q3 24
42.4%
-13.7%
Q2 24
50.4%
-18.9%
Q1 24
-81.6%
-23.4%
Capex Intensity
SAMG
SAMG
XTNT
XTNT
Q4 25
11.4%
1.2%
Q3 25
2.6%
1.3%
Q2 25
1.5%
1.0%
Q1 25
1.3%
3.6%
Q4 24
5.3%
2.1%
Q3 24
1.2%
7.5%
Q2 24
1.1%
1.9%
Q1 24
2.0%
2.8%
Cash Conversion
SAMG
SAMG
XTNT
XTNT
Q4 25
94.39×
Q3 25
23.62×
3.53×
Q2 25
7.22×
0.36×
Q1 25
-10.01×
22.03×
Q4 24
13.34×
Q3 24
5.90×
Q2 24
6.00×
Q1 24
-8.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

SAMG
SAMG

Investment Advisory Management And Administrative Service$30.7M96%
Tax And Family Office Services$1.2M4%

XTNT
XTNT

Orthobiologics$18.3M57%
Spinal Implant$9.4M29%
License Revenue$4.6M14%

Related Comparisons